|Quality of evidences (GRADE)||Recommendation||Strength of clinical recommendation|
|Very low||Starting a treatment for metastatic disease at the time of diagnosis, also without disease-related symptoms, is recommended. A wait-and-see period might be considered in well-selected cases (elderly, comorbidities, minimal tumour load) after an adequate evaluation of risks/benefits.62 63||Strong for|
|Moderate||A maintenance treatment with bevacizumab±fluoropyrimidine can be considered in patients with mCRC after a first-line treatment with bevacizumab, after an adequate evaluation of risks/benefits and patient’s motivation.16 17||Conditional for|
GRADE, Grading of Recommendations, Assessment, Development and Evaluations; mCRC, metastatic colorectal cancer.